This application relates to compounds of Formula (I):
or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
[EN] 1,2-DIAMIDO-ETHYLENE DERIVATIVES AS OREXIN ANTAGONISTS<br/>[FR] DÉRIVÉS DU 1,2-DIAMIDO-ÉTHYLÈNE
申请人:ACTELION PHARMACEUTICALS LTD
公开号:WO2009022311A3
公开(公告)日:2009-04-09
HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS
申请人:Incyte Corporation
公开号:US20200148689A1
公开(公告)日:2020-05-14
This application relates to compounds of Formula (I):
or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
[EN] 1,2-DIAMIDO-ETHYLENE DERIVATIVES<br/>[FR] DÉRIVÉS DU 1,2-DIAMIDO-ÉTHYLÈNE
申请人:ACTELION PHARMACEUTICALS LTD
公开号:WO2009022311A2
公开(公告)日:2009-02-19
The invention relates to 1,2-diamido-ethylene derivatives of the formula (I) wherein R1, R 2, R 3, and A are as described in the description and their use as medicaments, especially as orexin receptor antagonists.
[EN] HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE PI3K
申请人:INCYTE CORP
公开号:WO2020102198A1
公开(公告)日:2020-05-22
This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.